| Treatment Category | Treatment Name | Mechanism of Action | Evidence Level | Key Notes |
|---|---|---|---|---|
| Non-pharmacological | Exercise training (Levine Protocol) | Improves cardiac output, reverses deconditioning, increases orthostatic tolerance | Moderate | Reported benefit with structured recumbent-to-upright training; 53–71% of patients no longer met POTS criteria after 3 months in cited summaries (pqac-00000018, pqac-00000019) |
| Non-pharmacological | Salt supplementation (8–12 g/day) | Expands plasma volume | Expert consensus | First-line measure; commonly recommended with fluids for most patients (pqac-00000018, pqac-00000023) |
| Non-pharmacological | Fluid intake (2–3 L/day) | Expands intravascular volume | Expert consensus | First-line measure; often paired with sodium loading (pqac-00000018, pqac-00000020, pqac-00000023) |
| Non-pharmacological | Compression garments (20–30 mmHg) | Reduces venous pooling in lower extremities and abdomen | Moderate | Waist-high or thigh-high garments/abdominal binders preferred in reviews and management algorithms (pqac-00000017, pqac-00000020, pqac-00000021) |
| Non-pharmacological | Vagus nerve stimulation (tVNS) | Restores sympathovagal balance; may reduce inflammation | Emerging | Non-invasive option under study; highlighted as a possible first-line adjunct in recent reviews (pqac-00000010, pqac-00000021) |
| Pharmacological | Ivabradine | If-channel blocker in sinoatrial node; lowers heart rate without reducing blood pressure | RCT evidence | Frequently highlighted as one of the stronger pharmacologic options; Phase 3 trial completed: NCT03182725 (pqac-00000021, pqac-00000022, pqac-00000023, pqac-00000000) |
| Pharmacological | Beta-blockers (e.g., propranolol, bisoprolol) | Heart-rate reduction and sympatholytic effect | RCT evidence | Multiple options used clinically; improve tachycardia and symptoms in many patients (pqac-00000018, pqac-00000020, pqac-00000021, pqac-00000023) |
| Pharmacological | Midodrine | Alpha-1 adrenergic agonist causing peripheral vasoconstriction | Limited RCT | Often used for venous pooling/hypotension phenotype; hemodynamic benefit suggested in single studies (pqac-00000017, pqac-00000020, pqac-00000021) |
| Pharmacological | Fludrocortisone | Mineralocorticoid promoting sodium/water retention and volume expansion | Expert consensus | Commonly used in hypovolemic presentations; evidence base remains limited (pqac-00000018, pqac-00000022) |
| Pharmacological | Pyridostigmine | Acetylcholinesterase inhibitor; enhances parasympathetic/cholinergic tone | Limited RCT | Can improve fatigue/hemodynamics in selected patients; evidence from limited studies (pqac-00000017, pqac-00000018, pqac-00000021) |
| Immunotherapy | IVIG | Immunomodulation; may reduce pathogenic autoantibody effects | Case series/RCT | Considered for autoimmune-mediated refractory POTS; case series positive, but small RCT showed no clear advantage over albumin in one study (pqac-00000016, pqac-00000050, pqac-00000051) |
| Immunotherapy | Plasmapheresis | Removes circulating autoantibodies and immune mediators | Case series | Used in severe refractory cases; reported functional improvement in small series (pqac-00000050, pqac-00000051, pqac-00000057) |
| Immunotherapy | Rituximab | Anti-CD20 B-cell depletion | Case reports | Very limited evidence; reported in isolated autoimmune autonomic cases including POTS-related presentations (pqac-00000050, pqac-00000052, pqac-00000056) |
| Immunotherapy | Corticosteroids | Anti-inflammatory and immunosuppressive effects | Case reports | Considered when autoimmune contribution is suspected; evidence remains sparse and indirect (pqac-00000052, pqac-00000053, pqac-00000055) |


*Table: This table summarizes current POTS management strategies across non-pharmacological, pharmacological, and immunotherapy categories. It is useful for comparing mechanisms, strength of evidence, and key clinical notes from recent literature and trial context.*